Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.33 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18149287 | 0.87 | MAPT (0.39) | MAPTNPC1RAB9ATP53NR4A2 | |
| SCHEMBL18280256 | 0.82 | TP53 (0.44) | MAPTTP53NR4A2PARP10ALKBH1 | |
| SCHEMBL22420483 | 0.75 | TP53 (0.42) | MAPTTP53CHEK2 | |
| SCHEMBL18149075 | 0.74 | DYRK1A (0.46) | DYRK1A | |
| SCHEMBL25655675 | 0.68 | TP53 (0.41) | MAPTTP53 | |
| SCHEMBL15552361 | 0.65 | AAK1 (0.42) | MAPTRAB9ATP53LMNA | |
| SCHEMBL18280252 | 0.65 | TP53 (0.46) | MAPTTP53 | |
| SCHEMBL20508499 | 0.64 | DYRK1A (0.64) | DYRK1A | |
| SCHEMBL18280257 | 0.63 | TP53 (0.45) | MAPTNPC1RAB9ATP53 | |
| SCHEMBL18280255 | 0.62 | CYP1A2 (0.38) | MAPTNPC1RAB9AMAP4K4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080123-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-17 | — | — | EP | disclosed |
| US-9926313-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-03-27 | — | — | US | disclosed |
| US-20160304513-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304513-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | MAPT 2285/4885NPC1 3959/4885RAB9A 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.